Associated Papers
Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumours.
Ebbelaar CF et al.
Ebiomedicine, 2025
40107205 (PubMed )
Supplement: mmc1.docx
The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S et al.
Cancer, 2019
Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel.
de Unamuno Bustos B et al.
Scientific Reports, 2017
28356599 (PubMed )
Supplement: 41598_2017_606_MOESM2_ESM.xls › Table_S1
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
Ross RL et al.
Bmc Cancer, 2016
27465249 (PubMed )
Supplement: 12885_2016_2570_MOESM1_ESM.docx
Select a paper to view details